In this role, he will establish an office of entrepreneurship while working closely with senior leadership and investigators at Weill Cornell Medicine, Cornell’s Ithaca campus, Cornell Tech, the Tri-Institutional community, and other partners.
Dr. Shore will represent the WDOM on compliance matters related to the department, and provide leadership in support of the inpatient service to ensure high quality patient care.
In this pivotal role, he will work closely with Weill Cornell Medicine and NewYork-Presbyterian Hospital leadership to promote and ensure exceptional patient care in the ambulatory setting.
Dr. Melnick and his team have developed an SIRT3-blocking compound that rapidly kills diffuse large B cell lymphoma cells in the culture dish and in mice.
This award is presented annually to members of the Weill Department of Medicine below the rank of professor who perform on outstanding levels in the areas of clinical and/or basic biomedical research.
Dr. Silver received the award in recognition of his contributions to international integration of research in the field of leukemia.
A premier investigator in the areas of translational and clinical drug development, Dr. Hidalgo has been at the helm of the early clinical development of more than 50 new anticancer agents.
Pembrolizumab was administered to patients who had already undergone extensive chemotherapy for advanced esophageal cancer and who, subsequently, had not responded to any other treatment.
This therapy is primarily being studied for resistant prostate cancer that has spread and/or has not responded to hormonal therapy.
A preeminent hematologist, neuroscientist, administrator, and educator, Dr. Hempstead’s distinguished career at Weill Cornell has spanned more than 30 years.
